- Home
- INBX vs NBTX Comparison
INBX vs NBTX Comparison
Compare INBX & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBX
- NBTX
- Stock Information
- Founded
- INBX 2010
- NBTX 2003
- Country
- INBX United States
- NBTX France
- Employees
- INBX N/A
- NBTX N/A
- Industry
- INBX Biotechnology: Pharmaceutical Preparations
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- INBX Health Care
- NBTX Health Care
- Exchange
- INBX Nasdaq
- NBTX Nasdaq
- Market Cap
- INBX 222.5M
- NBTX 201.9M
- IPO Year
- INBX 2020
- NBTX 2020
- Fundamental
- Price
- INBX $16.21
- NBTX $4.20
- Analyst Decision
- INBX Hold
- NBTX Strong Buy
- Analyst Count
- INBX 1
- NBTX 2
- Target Price
- INBX N/A
- NBTX $11.50
- AVG Volume (30 Days)
- INBX 47.7K
- NBTX 6.6K
- Earning Date
- INBX 08-13-2024
- NBTX 11-19-2024
- Dividend Yield
- INBX N/A
- NBTX N/A
- EPS Growth
- INBX N/A
- NBTX N/A
- EPS
- INBX 118.83
- NBTX N/A
- Revenue
- INBX $1,687,000.00
- NBTX $45,220,186.00
- Revenue This Year
- INBX N/A
- NBTX N/A
- Revenue Next Year
- INBX N/A
- NBTX N/A
- P/E Ratio
- INBX $0.14
- NBTX N/A
- Revenue Growth
- INBX 24.26
- NBTX 526.17
- 52 Week Low
- INBX $10.80
- NBTX $4.07
- 52 Week High
- INBX $18.95
- NBTX $8.96
- Technical
- Relative Strength Index (RSI)
- INBX 56.54
- NBTX 40.06
- Support Level
- INBX $15.24
- NBTX $4.07
- Resistance Level
- INBX $16.79
- NBTX $4.44
- Average True Range (ATR)
- INBX 0.59
- NBTX 0.22
- MACD
- INBX 0.02
- NBTX -0.03
- Stochastic Oscillator
- INBX 62.56
- NBTX 13.00
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.